Inhibitors of the mitochondrial respiratory chain cytochrome bc 1 complex, such as the antimalarial atovaquone and ELQ-300, and many well-studied compounds, are classified as either Q o or Q i site inhibitors based on their site of action. Here, we investigated the site of action of ELQ-400 that showed an unusual behaviour, being effective against parasites resistant to the Q o site inhibitor atovaquone or to the Q i site inhibitor ELQ-300. Analysis of yeast mutants and comparison with atovaquone and other ELQs strongly suggest that ELQ-400 targets both Q o and Q i sites. Dual site inhibition would be particularly efficient as it would lower the risk of acquired resistance. However, such compounds are seldom found, which could be explained by structural and mechanistic differences between the sites.
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In eukaryotes, the cytochrome bc 1 complex or complex III of the respiratory chain is situated within the inner mitochondrial membrane. It is also commonly found in the respiratory chains of prokaryotes. It is a multisubunit enzyme with up to 11 subunits. Three subunits, cytochrome b, cytochrome c 1 and the iron-sulfur protein (ISP), contain the redox-active groups (b-and c-type haems and a [2Fe-2S] iron-sulfur cluster) and form the central core for electron (and associated proton) transfer chemistry. Atomic structures of several bc 1 complexes from different species are available, and share the same catalytic core, with cytochrome b as the central subunit. Cytochrome b is a predominantly hydrophobic protein with eight transmembrane helices which is encoded by the mitochondrial genome in all eukaryotes. All other components of the bc 1 complex are encoded as nuclear genes.
The bc 1 complex functions as a ubiquinol:cytochrome c oxidoreductase, coupling this electron transfer chemistry to proton movement across the inner mitochondrial membrane, contributing to the protonmotive force used by the ATP synthase. Its catalytic mechanism, the energy-conserving Q-cycle, bifurcates electron flow across two (high-and lowredox potential) electron transfer pathways within the complex [1, 2] . The basic mechanism of the Qcycle requires two distinct quinone-binding sites, the quinol oxidation site (Q o ) and the quinone reduction site (Q i ), located on opposite sides of the membrane which are linked by the low-potential transmembrane electron transfer pathway (via haems b L and b H ). Cytochrome b provides the Q o and the Q i sites, and the low-potential transmembrane electron chain, while the high-potential electron pathway from Q o Abbreviations ELQ, endochin-like quinolone; ISP, iron-sulfur protein; Q i , site quinone reduction site; Q o , site quinol oxidation site.
to cytochrome c is formed by ISP and cytochrome c 1 .
Quinol antagonists, as specific inhibitors of the bc 1 complex, have been known for decades. They represent invaluable tools for the study of the enzymatic mechanism. Well before the determination of atomic structures, they were classified into Q o and Q i site inhibitors based on their site of action, which was identified by using spectroscopic methods and/or a mutational approach [3] . Many cytochrome b mutations conferring inhibitor resistance were studied in model organisms, such as the yeast Saccharomyces cerevisiae.
bc 1 complex inhibitors are used as antiprotozoal and fungicide drugs to control human and plant pathogens. Most of these target the Q o site, as clearly proven by the report of resistance mutations in that site (see [4] and references within). Atovaquone, for instance, is used against Plasmodium falciparum, and also Toxoplasma gondii, Babesia microti and Pneumocystis jiroveci. Numerous cases of resistance have been reported in pathogens isolated from patients after treatment failure. This resistance is linked to Q o site mutations (for instance [5] [6] [7] [8] ). In P. falciparum, amino acid substitutions of Y268, the key residue for atovaquone binding [9] are frequently observed [10, 11] . These mutations, Y268C and Y268S, cause a high level of resistance as also observed in yeast [12] .
Because of the high occurrence of resistance, new drugs that can circumvent atovaquone resistance are currently being developed. Of particular interest are molecules binding in the Q i site (for instance, [13] [14] [15] [16] ). ELQs (endochin-like quinolones) are potent inhibitors of apicomplexan parasite bc 1 complex [17, 18] . ELQ-271 and ELQ-316, active against T. gondii, have been shown to target the Q i site [13, 19] . ELQ-300, active against P. falciparum and remarkably efficient against atovaquone-resistant parasites, is also reported as a Q i site inhibitor [14] . ELQ-400 was also reported as active against P. falciparum [20] and effective against atovaquone-resistant strains. However, the Q i site mutation I22L that causes resistance to ELQ-300 did not result in cross-resistance to ELQ-400, suggesting a different mode of action [14] .
In this study, we used yeast to investigate the target of ELQ-400. Yeast is a useful model for such study as this organism is amenable to mitochondrial transformation. Modifications of the mitochondrial DNAencoded cytochrome b are thus feasible. In addition, cytochrome b amino acid sequences, in particular at Q o and Q i sites, are well conserved between yeast and apicomplexan parasites, making yeast a pertinent model for the study of antimalarial drugs targeting the bc 1 complex.
Here, we tested the effect of single or multiple amino acid substitutions in the Q o and Q i sites on the sensitivity to ELQ-400, and other ELQs. This mutational approach showed that ELQ-400 could target both Q o and Q i sites, while other ELQs behave as classic single site inhibitors.
Materials and methods

Materials and growth media
Cytochrome c, decylubiquinol and atovaquone were obtained from Sigma Aldrich. ELQs were kindly provided by M. Riscoe, OHSU, USA. The following media were used for yeast growth: YPD (1% yeast extract, 2% peptone, 3% glucose) and YPG (1% yeast extract, 2% peptone, 2% glycerol).
Yeast strains
The mutations were introduced in yeast cytochrome b as described in [21, 22] . In all experiments, control and mutants have identical nuclear and mitochondrial genomes with the exception of the cytochrome b mutations gene. Growth experiments were performed using a standard strain derived from W303-1B, namely CWWT (a leu2-3,112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15 with intronless mitochondrial DNA) and strains derived from AD1-9 that lacks several membrane transporters (a ura3 his1, yor1D ::hisG, snq2D:: hisG, pdr5D:: hisG, pdr10D ::hisG, pdr11D ::hisG, ycf1D :: hisG, pdr3D::hisG, pdr15D ::hisG, pdr1D ::hisG) and kindly provided by M. Ghislain, UCL, Belgium.
Decylubiquinol-cytochrome c reductase activity
Yeast mitochondria were prepared as in [23] . Concentration of bc 1 complex in the mitochondrial samples was determined from dithionite-reduced optical spectra, using e = 28.5 mM À1 cm À1 at 562 nm minus 575 nm. Decylubiquinol-cytochrome c reductase activities were determined at room temperature by measuring the reduction of cytochrome c (final concentration of 20 lM) at 550 nm minus 540 nm over 1-min time-course in 10 mM potassium phosphate pH 7, 0.01% (w/v) lauryl-maltoside and 1 mM KCN. Mitochondria were added to obtain a final concentration of around 10 nM bc 1 complex. Activity was initiated by the addition of decylubiquinol and initial rates were measured. Each measurement was repeated 3-5 times and the values obtained were averaged. IC 50 (midpoint inhibition concentrations) were determined by inhibitor titration. TN (turnover) was determined as the cytochrome c reduction rate per bc 1 complex at 20 lM decylubiquinol. K M values were estimated from the plots of cytochrome c reduction rates vs decylubiquinol concentrations, as the decylubiquinol concentrations (2.5-40 lM) required to obtain 50% of the observed maximum rate of cytochrome c reduction.
Ligand docking and molecular modelling
An atomic model of ELQ-400 was generated using COR-INA version 3.60 (Molecular Networks GmbH, Erlangen, Germany, http://www.molecular-networks.com). The atomic coordinates of the yeast bc 1 complex 3CX5 were downloaded from the Protein Data Bank and used as receptor in the docking process. Water molecules in binding sites and haems were retained. Ligands, lipids and water molecules outside the two binding sites were removed, as well as all other chains except those close to cytochrome b and ISP. Hydrogen atoms were added using HERMES, the graphical interface of GOLD [24] . The docking of ELQ-400 was performed with GOLD using a binding site defined as a 20 A radius sphere centred on the d1-carbon atom of cytochrome b residue I147 (Q o site) and a 20
A radius sphere centred on the c-oxygen atom of cytochrome b residue S206 (Q i site). "Toggle" function for water molecules was activated. GoldScore was used as a scoring function and all other parameters had default values. In silico mutations were introduced using CHIMERA [25] , which was also used for generating the molecular modelling images.
Results and Discussion
Inhibition of yeast bc 1 complex activity by ELQ-400
We first tested the inhibitory effect of ELQ-400 on yeast wt bc 1 complex activity, measured as decylubiquinol-cytochrome c reductase activity. The obtained IC 50 value was compared with the IC 50 values for four others compounds: ELQ-271 and ELQ-316, potent Q i site inhibitors of T. gondii [13, 19] ; the Q o site inhibitor atovaquone; and ELQ-319. The chemical structures of these ELQs are shown in Fig. 1 .
ELQ-400 inhibits yeast bc 1 complex in the submicromolar range. The IC 50 value (reported per nM bc 1 complex) was around 88 nM. The compound displayed a lower activity compared to ELQ-271 and atovaquone. A similar IC 50 value was obtained for ELQ-319, whereas ELQ-316 was found to be inactive ( Table 1) . The ELQs are weaker inhibitors of the yeast enzyme than the stoichiometric inhibitor antimycin. In the same conditions, 50% inhibition was obtained with around 0.5 antimycin per bc 1 complex [26] . Thus, the IC 50 value for antimycin is > 100-fold lower than that for ELQ-400.
In parallel, we monitored the inhibitory effect of these compounds on yeast respiratory growth (Fig. 2) . We compared the growth of a standard strain CWWT with AD1-9 lacking several membrane transporters involved in drug efflux, which renders the cells more sensitive to added compounds in the growth medium, such as atovaquone [21] .
The growth of CWWT with the full set of membrane transporters was unaffected by the compounds, while AD1-9 was inhibited by ELQ-271 and ELQ-319, indicating that transporters inactivated in AD1-9 would be required for the efflux of these two compounds, as for that of atovaquone. ELQ-316 did not inhibit AD1-9 growth, which could be expected as the compound showed no effect on bc 1 complex activity. Less expected was the lack of effect of ELQ-400 on AD1-9 growth, as the drug inhibited the bc 1 complex activity with an IC 50 similar to that of ELQ-319. This suggests that ELQ-400 cannot reach its target even though several membrane transporters are inactive. Additional work would be required to identify the membrane transporter(s) that are presumably causing ELQ-400 efflux.
Effect of Q o and Q i site mutations on ELQ-400 sensitivity, and comparison with single site inhibitors A series of strains with single or multiple substitutions in either the Q o or the Q i site were then used to identify the target of ELQ-400. The amino acid substitutions of these mutants are listed in Table 2 .
Four Q o site mutants were studied. PF2, PF8 and PF-Y279 result from the replacement of several yeast residues by P. falciparum residues. PF-Y279S combined the atovaquone resistance mutation Y279S (Y268S in P. falciparum) with the 10 mutations of PF-Y279. We previously showed that PF-Y279S was markedly resistant to atovaquone, while PF-Y279 was sensitive, and PF2 and PF8 displayed a moderate increase of resistance [26, 27] .
Six Q i site mutants were analysed. M221Q was previously showed to confer resistance to ELQ-271 in yeast [13] . M221F, F225L and K228L replaced yeast residues by the P. falciparum equivalents. PFQi2 combined eight Plasmodium-like changes. In T. gondii, mutation of residue T222 (corresponding to K228 in yeast) in a proline was shown to cause resistance to ELQ-316 and ELQ-271 [19] .
We first monitored the respiratory growth sensitivity to several ELQs of the control and the Q i site mutants (Fig. 3) . All strains were derived from AD1-9. As expected, they were insensitive to ELQ-400. None were inhibited by ELQ-316. For ELQ-271, -233, -267 and -319, the same pattern of resistance was observed. M221Q conferred a marked resistance to these four drugs, while M221F seems to cause a weaker resistance. This observation indicates that ELQ-233, -267 and -319 target the Q i site, as does ELQ-271 and that the four drugs share the same binding mode. None of the Q i site mutants were resistant to atovaquone and none of the Q o site mutants were resistant to ELQ-271, as expected (not shown).
Mitochondria were then prepared from the Q o and Q i mutants and the bc 1 complex activities were monitored. None of the mutations had a severe effect on the catalytic site as K M and TN (turnover) values were only moderately changed (Data S1). The most affected mutants were PF-Y279 and PF-Y279S, as previously observed [26, 27] .
The sensitivity of the bc 1 complex activity to ELQ-400 was tested and the IC 50 values were determined (Fig. 4, top panel) . For comparison, we also determined the IC 50 of chosen mutants for the Q o site inhibitor atovaquone (right panel) and for the Q i site inhibitors ELQ-271 and -319 (left panel).
Replacement of the large residues F225 and K228 at the Q i site by the smaller residues leucine or isoleucine The plates were incubated for 3 days at 28°C. CWWT is a standard strain; AD1-9 has a decreased drug efflux capacity.
increased 2-to 5-fold the sensitivity to ELQ-400. The multiple changes of Plasmodium-like PFQi2 resulted in similar effect: sevenfold decreased IC 50 . The mutations might increase the accessibility of the drug to the Q i site or slightly stabilise its binding. M221Q and M221F had no or very minor effect on ELQ-400 sensitivity. By contrast, M221Q caused resistance to ELQ-271, as already reported, and to ELQ-319, as judged by the markedly increased IC 50 of the mutant, showing, as mentioned above, that both drugs target the Q i site and share a binding site. The absence of crossresistance to ELQ-400 suggests a different mode of action. We also tested the sensitivity of PFQi2 to ELQ-316 but the mutant bc 1 complex remained insensitive to that compound (not shown). It can be hypothesised that while the mutations render the site more easily accessible to ELQ-400, the additional bulky substituents (methoxy and chlorine) of ELQ-316 hinder its binding. Plasmodium and Toxoplasma Q i sites that can accommodate ELQ-316 might be larger than yeast Q i site, explaining the differential sensitivity to the drugs. More modifications of the yeast site would thus be needed to render it reactive to ELQ-316.
Modification of the Q o site also resulted in an increased sensitivity to ELQ-400 (Fig. 4) . PF-Y279, with 10 Plasmodium-like changes, displayed a 17-fold increased sensitivity with an IC 50 for ELQ-400 similar to that for atovaquone. The six changes of PF2 had no effect, while the five changes of PF8 resulted in sixfold increase in sensitivity. PF8 mutation had no effect on the sensitivity to ELQ-271 and ELQ-319 (left panel) and conferred, as previously reported, a mild (fourfold) resistance to atovaquone (right panel).
Thus, it seems that ELQ-400 accessibility and/or stabilization into the Q o pocket is enhanced by the Plasmodium-like modifications. Mutation at positions 283, 295, 296 and 299 (present in PF8 and PF-Y279, but not in PF2) would have the greatest impact.
The introduction of the atovaquone resistance mutation Y279S in PF-Y279 (PF-Y279S) caused a mild fourfold increase in ELQ-400 resistance (top panel), while it caused a major 250-fold increase in atovaquone resistance (right panel). This result is in agreement with the data obtained with P. falciparum growth assays. The sensitivity of the atovaquone-resistant parasite to ELQ-300, ELQ-316 and ELQ-271 was unchanged compared to control, while its sensitivity to ELQ-400 was 20-fold decreased [14] . This was a moderate resistance compared to the major > 3000-fold increased atovaquone resistance of the parasite, also found in the bacterial model [28] . As reported in a previous study [20] , parasites resistant to ELQ-400 were obtained after selection. The mutation V259L (V270 in yeast) was observed, which conferred a 10-fold increased resistance to ELQ-400 and atovaquone. The mutation, located in the Q o site region, might alter the local structure of the site and thus the binding of both drugs.
Thus, our mutational analysis in yeast showed that ELQ-400 could target both Q o and Q i sites, as mutations in either sites increased the drug sensitivity of the bc 1 complex. It is interesting to note that these mutations replaced yeast residues by the equivalent residues in P. falciparum, highly sensitive to ELQ-400. It was previously suggested that some of the ELQs could target simultaneously the two binding sites of the bc 1 complex [14] . The data obtained here with yeast mutants validate that hypothesis.
In silico models of ELQ-400 docking in Q i and Q o sites
In order to further analyse the data obtained with the Q i and Q o site mutants, in silico docking models of ELQ-400 binding were constructed. At the Q i site, ELQ-400 quinolone headgroup would bind in a manner similar to that of the substrate ubiquinol [9, 29] and of pyridones [15] (Fig. 5) .
We suggest that F225L that replaces a bulky aromatic side chain by a smaller aliphatic counterpart might allow the side chain of I26, which is in direct contact with the aromatic ring of the inhibitors (and substrate), to rotate. This would create more volume within the site for ELQ-400, potentially removing steric hindrance problems, and thus increasing the sensitivity of the mutant site. Interestingly, mutation of I26 (I22L in P. falciparum) caused resistance to ELQ-300 in the parasite [14] . The side chain of K228 (helix E) is hydrogen-bonded to the backbone amide of S28 (helix A). This hydrogen bond is lost in K228L/I and the flexibility between helix E and A might increase, which may create more volume in the Q i site for ELQ-400. This could explain the increased sensitivity of the mutants.
Interactions between ELQ-400 and the methionyl side chain of M221 (at the N-terminal region of the transmembrane helix E), separated by a closest approach of 3.1 A, is predicted to be a major stabilising influence for ligand binding. Mutation M221Q would thus result in a lower affinity of the compound to the site. However, as its affinity for the Q o site is not altered by the Q i site mutation, the overall sensitivity of the complex is unaffected. By contrast, the enzyme sensitivity to the single target Q i site inhibitors ELQ-217 and ELQ-319 is markedly decreased by M221Q.
At the Q o site, the endochin-like moiety would bind in a manner similar to that of stigmatellin and atovaquone (Fig. 6) . ELQ-400 is predicted to bind in a Fig. 3 . Effect of mutations in bc 1 complex Q i sites on the growth sensitivity to ELQs. Suspension in water of mutant and wt cells, all derived from AD1-9, were pregrown on glucose plates and then spotted on plates containing the respiratory medium YPG without or with ELQs. The drugs were added at the concentration of 0.1 lM (ELQ-271), 1 lM (ELQ-319) or 10 lM (ELQ-233, 267, 316 and 400). The plates were incubated for 3 days at 28°C.
predominantly hydrophobic pocket formed from components contributed by cytochrome b helices C, cd1 and F1, and the ef ('PEWY') and F1-F2 loops. A 2 A hydrogen bond is predicted between the histidyl side chain of ISP-residue H181 ([2Fe-2S] cluster ligand) and the quinolone NH group of ELQ-400. No other hydrogen bonding interactions are predicted between ELQ-400 and the protein backbone, although stabilising interactions with Q o -localised water molecules cannot be discounted given the large number of polar substituents on the ligand. A pi-pi interaction is predicted to occur between the tyrosyl side chain of cytochrome b ef-loop residue Y279 and the quinolone group of ELQ-400, with a separation of 2.8 A, with additional stabilizing interactions between PEWY-loop residue P271 and the ligand. Additional van der Waals interactions are predicted between the trifluoromethoxy group of ELQ-400 and the side chain of I269 located in the linker region between helix E and the ef-loop. Mutation Y279S would thus result in a major loss of the compound stabilisation in the Q o site. However, its binding to the Q i site being unaffected by the Q o site mutation, the modification of the overall sensitivity of the bc 1 complex is minor (fivefold increase). By contrast, Y279S resulted in a severe resistance to the single site inhibitor atovaquone.
Single and dual site inhibitors
Most bc 1 complex inhibitors bind to either Q o or Q i site, but not to both. There are sound mechanistic reasons for this assertion. During normal Q-cycle operation, the bc 1 complex is faced with the issue of apparently energetically unfavourable electron transfer chemistry and also the need for control of highly reactive SQ (semiquinone) intermediate species, which are capable of reducing molecular oxygen to biologically harmful superoxide (see for instance [2, [30] [31] [32] ). Accordingly, the Q i and Q o sites are considered to have evolved to minimise these unwanted electron transfer reactions, but apparently through different mechanistic means [33] . In part, this is necessitated by thermodynamic constraints. At the Q i site, the relatively positive redox potential of haem b H with a E m,7 (midpoint redox potential at pH 7) of + 50 mV, is, at first glance, problematic for the first electron transfer reaction in the reduction of substrate ubiquinone (the midpoint potential of the ubiquinone/ubisemiquinone couple is % À160 mV in aqueous solution). The enzyme solves this problem by tightly binding the SQ intermediate at Q i (presumably through hydrogen bonding and other dipolar interactions [34] ), making the first electron transfer reaction more energetically favourable, with the additional bonus of reducing SQ reactivity with oxygen. In contrast, at the Q o site where the thermodynamic 'heavy lifting' for quinol oxidation is performed by the high-potential redox chain (i.e. ISP and cytochrome c 1 ), SQ reactivity has been proposed to be limited by strongly destabilising this intermediate, lowering the probability of unwanted electron transfer bypass reactions. Here SQ is likely to be a mobile species within the Q o pocket [33, [35] [36] [37] without significant ligand-protein interactions during critical electron transfer reactions (although see [38] for an alternative viewpoint).
Thus as a consequence, we consider that the structural differences between the Q o and Q i sites necessitated by the energetic and kinetic needs for efficient quinol/quinone redox chemistry make the design of a common, tightly binding antagonist for both sites a nontrivial prospect. NQNO, a molecule that structurally resembles the substrate quinol/quinone, is able to bind at both sites but with a relatively low affinity to either site ( [39] and refs within). Yeast NQNO resistant mutants were selected and mutations were only found in the Q i site; among them, M221Q and F225L studied in the present work. Therefore, NQNO is reported as a Q i site inhibitor. Ascochlorin also binds at both catalytic sites of the complex, as observed on bacterial and animal bc 1 complexes [40] . However, no resistance mutations related to this compound have been reported. ELQ-400 could thus be added to that very short list as it shows that unusual dual binding at both Q i and Q o sites.
Dual site inhibition would be protective against acquired drug resistance, as high-level resistance would require the simultaneous appearance of at least two mutations in cytochrome b of the parasite, which may be expected to cause fitness penalty [41] . So far, in P. falciparum, only a mutation at the Q o site, V259L, conferring a low level of resistance to ELQ-400 has been observed after selection [20] . Thus, compounds such as ELQ-400 would be much less susceptible to drug resistance.
In conclusion, designing molecules with favourable hydrogen bond donors and acceptors to bind at both Q o and Q i site seems feasible, although they might not have a strong affinity for both sites, presenting a problem (and paradox) for drug development. Thus, the best form of bc 1 chemotherapy might not be monotherapy, but a combination therapy approach. It was reported that the combination of the Q o site inhibitor atovaquone with the Q i site targeting ELQ-300 was remarkably efficient in the mouse model of malaria [42] . Thus, if dual site inhibitors are indeed scarce compounds, the combination of two tight-binding site-specific drugs may provide a more effective solution. 42 
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